Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M12,817Revenue $M3,324Net Margin (%)8.6Altman Z-Score3.5
Enterprise Value $M13,400EPS $3.8Operating Margin %24.1Piotroski F-Score6
P/E(ttm)47.1Beneish M-Score-2.6Pre-tax Margin (%)13.4Higher ROA y-yN
Price/Book7.310-y EBITDA Growth Rate %11.2Quick Ratio1.8Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %8.5Current Ratio2.3Lower Leverage y-yY
Price/Free Cash Flow25.5y-y EBITDA Growth Rate %-52.8ROA % (ttm)5.7Higher Current Ratio y-yN
Dividend Yield %0.5PEG5.4ROE % (ttm)15.7Less Shares Outstanding y-yY
Payout Ratio %23.0Shares Outstanding M74.3ROIC % (ttm)29.7Gross Margin Increase y-yY

Gurus Latest Trades with BCR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impact Price Range
(Average)*
Current Price Change from Averagedown Comment Current Shares
BCRJoel Greenblatt 2015-03-31 Add0.04%$164.52 - $178.59
($171.43)
$ 172.631%Add 213.81%44,492
BCRDonald Yacktman 2015-03-31 Reduce-0.79%$164.52 - $178.59
($171.43)
$ 172.631%Reduce 25.34%3,326,670
BCRYacktman Fund 2015-03-31 Reduce-0.75%$164.52 - $178.59
($171.43)
$ 172.631%Reduce 25.10%1,570,000
BCRYacktman Focused Fund 2015-03-31 Reduce-0.71%$164.52 - $178.59
($171.43)
$ 172.631%Reduce 24.41%1,220,000
BCRRobert Olstein 2014-12-31 Sold Out -0.63%$144.77 - $172.68
($161.89)
$ 172.637%Sold Out0
BCRDonald Yacktman 2014-12-31 Reduce-1.17%$144.77 - $172.68
($161.89)
$ 172.637%Reduce 30.85%4,455,796
BCRYacktman Focused Fund 2014-12-31 Reduce-0.82%$144.77 - $172.68
($161.89)
$ 172.637%Reduce 24.93%1,614,000
BCRYacktman Fund 2014-12-31 Reduce-1.42%$144.77 - $172.68
($161.89)
$ 172.637%Reduce 35.51%2,096,000
BCRVanguard Health Care Fund 2014-12-31 Reduce-0.05%$144.77 - $172.68
($161.99)
$ 172.637%Reduce 12.16%912,700
BCRJoel Greenblatt 2014-12-31 Reduce-0.31%$144.77 - $172.68
($162.11)
$ 172.636%Reduce 93.82%14,178
BCRVanguard Health Care Fund 2014-09-30 Reduce-0.04%$142.3 - $153.13
($147.7)
$ 172.6317%Reduce 10.22%1,039,100
BCRRobert Olstein 2014-09-30 Reduce-0.08%$142.3 - $153.13
($147.7)
$ 172.6317%Reduce 10.53%34,000
BCRYacktman Fund 2014-09-30 Reduce-0.1%$142.3 - $153.13
($147.7)
$ 172.6317%Reduce 2.40%3,250,000
BCRDonald Yacktman 2014-09-30 Reduce-0.15%$142.3 - $153.13
($147.81)
$ 172.6317%Reduce 3.85%6,443,334
BCRJoel Greenblatt 2014-09-30 Add0.27%$142.3 - $153.13
($147.81)
$ 172.6317%Add 470.83%229,325
BCRYacktman Focused Fund 2014-09-30 Reduce-0.22%$142.3 - $153.13
($147.81)
$ 172.6317%Reduce 6.52%2,150,000
BCRRobert Olstein 2014-06-30 Add0.15%$136.23 - $149.25
($142.86)
$ 172.6321%Add 26.67%38,000
BCRVanguard Health Care Fund 2014-06-30 Reduce-0.28%$136.23 - $149.25
($142.86)
$ 172.6321%Reduce 37.07%1,157,400
BCRYacktman Fund 2014-06-30 Reduce-0.12%$136.23 - $149.25
($142.86)
$ 172.6321%Reduce 2.76%3,330,000
BCRJoel Greenblatt 2014-06-30 Add0.05%$136.23 - $149.25
($142.86)
$ 172.6321%Add 187.29%40,174
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BCR is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BCR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Naughton Gail KDirector 2015-04-28Sell763$170.610.44view
Thompson Tommy GDirector 2015-04-28Sell1,200$170.430.55view
RING TIMOTHY MChairman and CEO 2015-03-23Sell7,628$170.650.42view
BRESLAWSKY MARC CDirector 2015-02-24Sell7,200$174.37-1.73view
RING TIMOTHY MChairman and CEO 2015-02-23Sell20,000$176.33-2.82view
DeFord John ASr. VP Sci Tech and Clin Afrs 2015-02-20Sell2,987$174.85-2view
HOLLAND CHRISTOPHER SSenior Vice President and CFO 2015-02-20Sell16,091$176.03-2.65view
WEILAND JOHN HPresident and COO 2015-02-19Sell8,413$174.99-2.07view
Luboff Sharon MGroup Vice President 2015-02-19Sell1,117$174.42-1.75view
Groetelaars John PGroup Vice President 2015-02-19Sell4,566$175.14-2.16view

Quarterly/Annual Reports about BCR:

News about BCR:

Articles On GuruFocus.com
Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
Reversing a Declining Pattern in Earnings Per Share Feb 24 2015 
Teleflex Declares Its Quarter Four Results Feb 24 2015 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 
Weekly 52-Week Highs Highlight: LBTYK, STZ, FISV, BCR Nov 09 2014 
Dividend Aristocrats In Focus Part 19 of 54: CR Bard Oct 15 2014 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
No More a Simple Distributor Sep 07 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 

More From Other Websites
Bard to Host Earnings Conference Call on July 23, 2015 Jul 01 2015
CR Bard's Lutonix DCB Proves Effective in LEVANT 2 Study - Analyst Blog Jun 26 2015
Prostate Cancer Devices Market – Trends, Forecast, and Growth Prospects Published by Technavio Jun 25 2015
The New England Journal of Medicine publishes LEVANT 2 results for the Lutonix® Drug Coated... Jun 25 2015
The New England Journal of Medicine publishes LEVANT 2 results for the Lutonix® Drug Coated... Jun 25 2015
Covidien agrees to settle some cases over transvaginal mesh devices Jun 24 2015
Henry Schein's Buyout Plan Eyes Nordic Animal Health Market - Analyst Blog Jun 24 2015
BARD C R INC /NJ/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 18 2015
Edited Transcript of BCR presentation 12-May-15 11:20pm GMT Jun 16 2015
Bard Announces $500 Million Share Repurchase Authorization Jun 10 2015
Bard Increases Quarterly Dividend Jun 10 2015
Bard Announces $500 Million Share Repurchase Authorization Jun 10 2015
Bard Increases Quarterly Dividend Jun 10 2015
C. R. Bard's Lutonix DCB Gets Full Reimbursement Approval - Analyst Blog Jun 10 2015
CMS Further Improves Reimbursement for Lutonix DCB for Outpatient Use Jun 09 2015
CMS Further Improves Reimbursement for Lutonix DCB for Outpatient Use Jun 09 2015
Top trades for the 2nd half: COST, LPL, SCHW & NVDA May 27 2015
Bard to Present at Jefferies Healthcare Conference May 26 2015
Bard to Present at Jefferies Healthcare Conference May 26 2015
BARD C R INC /NJ/ Files SEC form 8-K, Other Events May 06 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK